Navigation Links
Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results
Date:1/20/2009

g as part of HIV combination therapy in treatment-naive adults and traditional approval as twice-daily for use in treatment-experienced adult patients. Outside the United States, the European Commission granted full approval of the Marketing Authorization of PREZISTA in combination with ritonavir and other antiretroviral medicinal products for the treatment of HIV-1 infection, and extended the indication to include all treatment-experienced adult patients.

Worldwide, the Medical Devices and Diagnostics segment achieved annual sales of $23.1 billion in 2008, representing an increase over the prior year of 6.4% with operational growth of 3.5% and a positive currency impact of 2.9%. Domestic sales increased 1.0%, while international sales increased 11.3% (5.8% from operations and 5.5% from currency).

Primary contributors to the operational growth included Ethicon Endo-Surgery's minimally invasive products; Vistakon's disposable contact lenses; and DePuy's orthopaedic joint reconstruction and sports medicine businesses. This growth was partially offset by lower sales in the Cordis franchise, reflecting new competitive entries in the drug-eluting stent market.

During the quarter, the Company completed the acquisition of SurgRx, Inc., a privately held developer of the advanced bipolar tissue sealing system used in the ENSEAL family of devices, and the divestiture of Ethicon's Professional Wound Care business to One Equity Partners. In addition, the Company completed the acquisition of Omrix Biopharmaceuticals, Inc., a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products.

Also in the quarter, the Company entered into a definitive agreement to acquire Mentor Corporation, a leading supplier of medical products for the global aesthetic market.

The Company also announced 510(k) clearance from the FDA for the VITROS 5600 Integrated Syste
'/>"/>

SOURCE Johnson & Johnson
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine news :

1. Johnson & Johnson to Participate in Bear Stearns 20th Annual Healthcare Conference
2. Draxis Health selected by Johnson and Johnson Consumer Companies, Inc. for major contract manufacturing relationship
3. Johnson & Johnson Campaign for Nursings Future Joins With AACN to Offer New Minority Nurse Faculty Scholars Program
4. Trust for Americas Health Receives $7.6 Million Grant from the Robert Wood Johnson Foundation to Advance the Quality and Impact of the Public Health System
5. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
6. Johnson & Johnson Tops Annual Pharmaceutical Company Rankings in a New Report From Industry-Leading Publication Scrip
7. Independence Technology, A Johnson & Johnson Company, Renews Its Contract With Creative Technology Services
8. Johnson & Johnson Launches Global Diabetes Institute to Provide State-of-The- Art Education, Training to Health Professionals
9. Robert Wood Johnson Foundation Announces $15.6 Million Grant to Apply Power of the Archimedes Model to Critical Health Care Decisions
10. UAN Mourns Passing of President Cheryl L. Johnson, RN
11. Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... They know every second counts. And when it ... offers some of the best care in the nation. For the past two months, ... average blood clot removal time in the country. During the months of June and ...
(Date:8/3/2015)... Angeles, California (PRWEB) , ... August 03, 2015 ... ... Fifth Circuit Court of Appeals ruled in favor of the firm’s client Rebecca ... ), North Cypress Medical Center must reimburse benefits for Hamsher’s residential treatment for ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... researchers from the University of Pittsburgh School of Medicine are leading a five-year, ... drugs in sub-Saharan Africa. , A cooperative agreement awarded by the U.S. ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novation, the nation’s largest healthcare ... lab testing and precision medicine solutions that can help pharmacists and other healthcare ... than 8.6 million adverse drug events are reported in the U.S. Pharmacogenetic ...
(Date:8/3/2015)... ... August 03, 2015 , ... Catalent Pharma ... drugs, biologics and consumer health products, today welcomed the announcement by OPKO Health ... Drug Application for a new treatment for chronic kidney disease (CKD) and vitamin ...
Breaking Medicine News(10 mins):Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 2Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 3Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3
... 3, 2011) A drug that targets a specific ... than half of the people who take it. The drug, ... the results from the largest group of patients to take ... presented at the annual meeting of the American Society of ...
... of Allergy and Infectious Diseases (NIAID), part of the National ... exposed to HIV shut down, and how they can be ... of surface proteins that the immune system can use, like ... activate the cell or to damp down its activity. However, ...
... research study investigates the challenges that pen and ... the use of electronic health records. Understanding these ... supported by health IT. Focusing on referrals ... from the specialists back to the referring physician, ...
... Journal of Traumatic Stress finds that for ... happily married, communicating frequently with one,s spouse through letters ... of posttraumatic stress disorder (PTSD) symptoms after returning home. ... soldiers who returned from military deployment within the past ...
... By Amanda Gardner HealthDay Reporter , THURSDAY, ... dangerous strain of E. coli bacteria in Europe ... experts say. "Bacteria are constantly mutating and changing. They,re ... different," said Dr. Bruce Hirsch, an attending physician in infectious ...
... 10-page letter addressed to Donald Berwick, administrator of the ... The ACP strongly supports the intent of the ... potential of supporting such important care delivery goals as ... pleased that,the foundation of care under this payment model, ...
Cached Medicine News:Health News:Benefit of targeted lung cancer therapy confirmed 2Health News:Paper and computer workarounds challenge but may improve health IT 2Health News:Paper and computer workarounds challenge but may improve health IT 3Health News:Letters from home may help prevent post-traumatic stress disorder in happily married soldiers 2Health News:Deadly E. Coli Strain in Europe Should Serve as Warning, Experts Say 2Health News:Deadly E. Coli Strain in Europe Should Serve as Warning, Experts Say 3Health News:Supportive of intent of ACO proposed rule, ACP expresses concern 2Health News:Supportive of intent of ACO proposed rule, ACP expresses concern 3
(Date:8/3/2015)... -- ReportsnReports.com adds Global Medical Simulation ... as well as Global Medical Simulation Market 2015-2019 ... of its library. Complete 2015 report ... across 164 pages, talking about 7 major companies ... now available at http://www.reportsnreports.com/reports/407046-global-medical-simulation-industry-report-2015.html . ...
(Date:8/3/2015)... , Aug. 3, 2015  Depomed, Inc. (NASDAQ: ... Horizon Pharma plc,s (NASDAQ: HZNP ) ("Horizon") announcement ... Directors ("Depomed Board") set a record date to determine ... The Depomed Board will review the request ... received today and contains the information required under Depomed,s ...
(Date:8/3/2015)... Va. , Aug. 3, 2015  Dr. ... joining Orthopaedic & Spine Center today, ... to manage their chronic pain through psychological counseling ... is a Fellowship-trained, certified medical psychologist with ... medicine. His vast experience ranges from assessment and ...
Breaking Medicine Technology:Medical Simulation Market to see 14% CAGR to 2019 2Medical Simulation Market to see 14% CAGR to 2019 3Medical Simulation Market to see 14% CAGR to 2019 4Medical Simulation Market to see 14% CAGR to 2019 5Medical Simulation Market to see 14% CAGR to 2019 6Depomed Comments on Horizon Pharma Announcement 2Depomed Comments on Horizon Pharma Announcement 3Depomed Comments on Horizon Pharma Announcement 4Depomed Comments on Horizon Pharma Announcement 5Depomed Comments on Horizon Pharma Announcement 6Orthopaedic & Spine Center Introduces New Pain Psychologist 2
... Diagnostics Incorporated (NYSE: DGX ), the world,s leading ... its Board of Directors declared a quarterly cash dividend of ... of record of Quest Diagnostics common stock on April 3, ... Quest Diagnostics is the world,s leading provider of diagnostic testing, ...
... 28, 2012 HistoRx, the leader in quantitative ... technology and critical elements of digital microscopy standardization.  ... the US Patent & Trademark Office advance the ... pathology to a dominant role in the industry.  ...
Cached Medicine Technology:HistoRx Achieves Dominant Intellectual Property Position in Standardization of Results from Digital Pathology Instruments 2HistoRx Achieves Dominant Intellectual Property Position in Standardization of Results from Digital Pathology Instruments 3
Human based assayed sera available in three levels for the control of accuracy and precision for up to 25 analytes...
The AMY method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of amylase activity in serum, plasma and urine....
For the quantitative in vitro determination of Aspartate Aminotransferase (AST) in serum and plasma....
This is an Immunological assay intended for the quantitative in vitro determination of haemoglobin A1c (HbA1c) in whole blood....
Medicine Products: